ASTRAZEN

** AstraZeneca Pharma India ASTR.NS shares up 11.5% at 8,885 rupees, marking their biggest pct jump so far this year

** ASTR on Friday reported 48% surge in Q4 profit on strong performance of oncology and biopharma divisions

** AstraZeneca shares up 21.6% YTD vs 8.8% fall in Nifty pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected] ))

May 29 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT OSIMERTINIB TABLETS

Source text: ID:nNSE5r4vcG

Further company coverage: ASTR.NS

(([email protected];;))

May 8 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES APPROVAL FOR ENHERTU IN INDIA

Source text: ID:nNSEXz4FK

Further company coverage: ASTR.NS

(([email protected];;))

April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS

• DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY

• HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA

• NEVER MARKETED OLAPARIB INDICATION IN INDIA

Source text: ID:nBSE1YlFfg

Further company coverage: ASTR.NS

(([email protected];;))

March 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• DISCONTINUING MANUFACTURING, MARKETING OF PROLONGED RELEASE ISOSORBIDE-5-MONONITRATE TABLETS BP

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];))

** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month

** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution

** Drug is used to treat patients with a certain type of lung cancer

** Shares trading above 50-, 100-, 200-day moving avg

** ASTR up 2.2% YTD, after gaining 32% in 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

March 7 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB SOLUTION

• PERMISSION PAVES WAY FOR MARKETING DURVALUMAB SOLUTION IN INDIA

Source text: ID:nNSEb26vVv

Further company coverage: ASTR.NS

(([email protected];;))

March 6 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS OF LOKELMA

Source text: ID:nNSE5FXNVQ

Further company coverage: ASTR.NS

(([email protected];;))

** AstraZeneca Pharma ASTR.NS rises 2.7% to 6,872.1 rupees; stock's biggest one-day gain since Feb. 3

** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution

** Drug is used to treat patients with a certain type of liver cancer

** Shares mark second-busiest session in about 2 weeks, with more than 11,000 shares traded

** Stock down 8% so far this year, after a 32% gain from 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Feb 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB FOR ADDITIONAL INDICATION

• GETS PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA

Source text: ID:nNSE3QqT8W

Further company coverage: ASTR.NS

(([email protected];;))

** Astrazeneca Pharma India ASTR.NS rises 2% to 7,609 rupees

** Q3 profit before exceptional item and tax jumps ~3.7x y/y, helped by strong demand for its oncology products; rev up 44%

** Co incurred one-off 335.5 million rupees ($3.9 mln) employee separation cost in the quarter

** More than 41,000 shares traded, 1.5x the 30-day avg

** Stock rose 32% in 2024

($1 = 86.8200 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Feb 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• DEC-QUARTER PAT 308.5 MILLION RUPEES

• DEC-QUARTER REVENUE FROM OPERATIONS 4.4 BILLION RUPEES

Source text: ID:nBSE7glxPw

Further company coverage: ASTR.NS

(([email protected];;))

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window

Feb 6 (Reuters) - European shares hovered near a record high on Thursday, buoyed by a raft of upbeat earnings, including drugmaker AstraZeneca, and ahead of the Bank of England's monetary policy verdict which is likely to result in an interest rate cut.

The pan-European STOXX 600 index .STOXX was up 0.5% as of 0813 GMT, trading near a record high last hit on January 31.

Heavyweight healthcare sub-index .SXDP jumped 0.8%, lifted by a 3.2% rise in AstraZeneca AZN.L, which forecast its 2025 sales above analysts' expectations after the drugmaker's fourth-quarter revenue beat estimates.

The earnings also boosted Britain's benchmark FTSE 100 .FTSE, which rose 0.8%.

Basic Resources .SXPP was the top winning sector, adding 2% after Europe's largest copper producer Aurubis NAFG.DE reported first-quarter pretax profit above market expectations.

All eyes were on the BoE that is expected to bring the key rate down to 4.5% from 4.75% in a bid to boost Britain's sluggish economy amid still-strong inflation pressures.

On the data front, HCOB's January Construction PMI and retail sales figures for the euro zone are scheduled for later in the day.

In other stocks, Maersk MAERSKb.CO rose 7.5% after it reported fourth-quarter profit above forecasts.

(Reporting by Nikhil Sharma in Bengaluru; Editing by Mrigank Dhaniwala)

(([email protected];))

By Maggie Fick

LONDON, Feb 5 (Reuters) - AstraZeneca AZN.L investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.

The group said on Oct. 31 that its China head Leon Wang, who also led its international business as an executive vice president, had been detained by the Chinese authorities. It said it did not know what the investigation was about.

Unless the company discloses fresh information about the probe and arrest at the release of fourth-quarter results, investors are likely to resume selling the stock even though the company's drug pipeline is viewed as strong, four healthcare investors and four analysts told Reuters.

"This blindsided the company," said AstraZeneca shareholder Lucy Coutts at investment firm JM Finn, noting the "void" of information about the probe.

"We don't have visibility on how or when this will be resolved," said Redburn Atlantic analyst Simon Baker. "This is the focus at the moment. It shouldn't be, but it is."

Wang's arrest was followed by other revelations, including that more than 100 former sales staff in China had been sentenced to jail time in a large and ongoing medical insurance fraud case.

In November the company reported a third investigation in China involving two current and two former senior executives, relating to the import of AstraZeneca cancer drugs from Hong Kong. It said the probe targeted only the individuals, not the company.

AstraZeneca declined to comment for this article ahead of results.

China has long been a key market for the drugmaker, the crown jewel of its international business that accounted for 13% of total sales in 2023.

The Anglo-Swedish group announced plans in 2023 to build a $450 million factory in China. It signed several licensing deals with Chinese companies that year, and bought a China-headquartered biotech company.

Chief Financial Officer Aradhana Sarin told investors at the JPMorgan Healthcare Conference last month the company anticipates some revenue impact on its China business in the fourth quarter and into 2025. Investors are hoping for more information on Thursday.

SMALL RECOVERY

AstraZeneca shares have recovered after the initial news of Wang's detention wiped around $18 billion off their value. They are up about 2% since early November.

In December, AstraZeneca replaced Wang with senior executive Iskra Reic as executive vice president for international, based in Shanghai.

Several investors said it may be tough for an executive who does not speak Mandarin and has never lived in China to navigate such a complicated market at a very sensitive time.

Barclays analysts said in a recent note they believe AstraZeneca may pay a penalty to resolve the Wang investigation. In 2014, British drugmaker GSK GSK.L was fined nearly 300 million pounds ($372 million) by a Chinese court for bribery.

"Whilst there could be some commercial impact coming from lack of promotion whilst the investigation is ongoing, we view this as digestible given the momentum elsewhere in the business," Barclays said.

($1 = 0.8054 pounds)

(Reporting by Maggie Fick; Editing by Josephine Mason and Jan Harvey)

(([email protected]; +44 7890 916706;))

Adds new items, updates futures

Feb 4 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Tuesday, with futures FFIc1 down 0.18%.

* DIAGEO: Diageo DGE.L withdrew its medium-term organic sales growth target, citing macroeconomic and geopolitical uncertainty.

* VODAFONE: Vodafone VOD.L reported another deterioration in Germany in its third quarter, a weak point amid otherwise stronger trading in Britain, Turkey and Africa.

* CREST NICHOLSON: Housebuilder Crest Nicholson CRST.L posted a 53% drop in 2024 fiscal year earnings, in line with market view.

* TULLOW OIL: Tullow Oil TLW.L said it has appointed its finance chief Richard Miller as interim chief executive officer, effective Feb. 14.

* RIO TINTO: Rio Tinto RIO.AX, RIO.L said on Tuesday it had begun clearing iron ore ships from two Western Australian ports as two tropical cyclones offshore swell seas and complicate efforts to repair infrastructure damaged by a previous cyclone last month.

* AstraZeneca: Britain on Monday hit back at AstraZeneca AZN.L over the collapse of a 450 million pound ($558.5 million) investment, saying it had scaled back the research and development portion of its plans, resulting in a lower offer of government support.

* GENERAL PHARMACEUTICAL COUNCIL: Britain's pharmacies regulator tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving drugs that could cause them harm.

* OIL: U.S. crude prices fell by nearly 2% as U.S. tariffs on China took effect

* METALS: LME copper prices edged higher after a sharp pullback in the previous session

* GOLD: Gold prices firmed as U.S. tariff and inflation concerns boosted safe-haven demand.

* For more on the factors affecting European stocks, please click on: LIVE/

TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB

(Reporting by Raechel Thankam Job)

(([email protected]))

Adds government response in paragraphs 9-10, other investment in paragraph 8

LONDON, Jan 31 (Reuters) - AstraZeneca AZN.L on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England, citing a cut in British government support.

The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain to generate economic growth.

"Following discussions with the current government, we are no longer pursuing our planned investment at Speke," a spokesperson for the London-listed bluechip drugmaker said in a statement.

"Several factors have influenced this decision, including the timing and reduction of the final offer compared to the previous government's proposal."

Earlier this week finance minister Rachel Reeves named AstraZeneca as one of the "great companies" she said were delivering jobs and investment across the country.

Her speech, focused on how to get the country's stagnant economy growing again, set out the importance of attracting investment and said the government was "determined to make Britain the best place in the world to invest".

The spokesperson for AstraZeneca, which also plans to spend 200 million pounds to expand its existing Cambridge presence, said the Liverpool site would continue to produce flu vaccines.

Over the past year, the company has set out billions of dollars worth of investment in various countries, from Singapore and Thailand to France and Canada.

The most notable among those was the Anglo-Swedish drugmaker's $2 billion spending proposal on research and development and manufacturing plants in the United States.

Britain's finance ministry said a change in "the make-up" of the investment originally proposed by AstraZeneca had led to a reduced government grant offer being made.

"All government grant funding has to demonstrate value for the taxpayer and unfortunately, despite extensive work from government officials, it has not been possible to achieve a solution," a government spokesperson said.

The Financial Times reported in August 2024 that AstraZeneca had warned it could relocate its vaccine manufacturing site from Britain to the United States as talks with the Labour government over state aid had become deadlocked.

The newspaper said Reeves wanted to reduce state provisions to the company's vaccine centre, which would cut the pledge made by the previous administration from about 90 million pounds to 40 million pounds.

The previous government's offer included up to 70 million in grants to develop the facility in Speke, the FT report said.

($1 = 0.8060 pounds)

(Reporting by Maggie Fick in London, Yamini Kalia in Bengaluru, additional reporting by Muvija M, writing by William James; Editing by Kate Holton and Jan Harvey)

(([email protected];))

Jan 7 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES ORDER FROM TRANSFER PRICING OFFICER

• CLAIM QUANTUM IS 119.6 MILLION RUPEES

Source text: ID:nNSE67pMWM

Further company coverage: ASTR.NS

(([email protected];;))

** Shares of Astrazeneca Pharma India Ltd ASTR.NS jump 8.3% to 6,888.90 rupees, set for its best day in 3 months

** Drugmaker confirms job losses in its biopharma unit but does not disclose number of employees affected

** The Economic Times daily reported earlier in the day that about 125 employees, or half of the biopharma unit's workforce, is being laid off

** About 194,000 shares traded, 14.6x 30-day avg volume

** Stock extends YTD gains to ~25%, set for third-straight year of growth

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Nov 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - GETS PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION OF LYNPARZA

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];;))

Nov 18 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - WILL LAUNCH BREZTRI AEROSPHERE IN JANUARY 2025

• ASTRAZENECA PHARMA INDIA LTD - LAUNCH OF BREZTRI AEROSPHERE IN JANUARY 2025 IN INDIA

Source text: ID:nNSE39rtGm

Further company coverage: ASTR.NS

(([email protected];;))

** Shares of Astrazeneca Pharma India ASTR.NS fall 5.1% to 6773.5 rupees

** Co posts 27% y/y drop in Q2 consolidated net profit to 384.3 mln rupees ($4.5 mln)

** ASTR set for worst session since Aug. 8, when it fell 6.6% on Q1 net loss

** However, stock on track to end week in the green, snapping a 3-week losing run

** ASTR up 24% YTD

($1 = 84.4000 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Nov 13 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SEPT-QUARTER PAT 384.3 MILLION RUPEES

• SEPT-QUARTER REVENUE FROM OPERATIONS 4.08 BILLION RUPEES

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];;))

Sept 25 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SHIPLA DIVEKAR NIRULA UNANIMOUSLY ELECTED AS CHAIRPERSON

Source text for Eikon: ID:nBSEbYnldj

Further company coverage: ASTR.NS

(([email protected];;))

** Shares of AstraZeneca Pharma India ASTR.NS up 7% to 7225 rupees

** Drugmaker gets India govt permission to import Durvalumab 120 mg and 500 mg solution for infusion (Imfinzi)

** Import nod for sale, distribution, ASTR says

** Durvalumab is a drug used in treatment of cancers such as liver and gall bladder cancers

** YTD stock has gained ~31%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Sept 23 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVED PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION OF DURVALUMAB

• RECEIPT OF THIS PERMISSION PAVES WAY FOR LAUNCH OF DURVALUMAB IN INDIA

Source text for Eikon: ID:nNSE90kGdc

Further company coverage: ASTR.NS

(([email protected];;))

Aug 8 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• JUNE-QUARTER LOSS AFTER TAX 117.9 MILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 3.88 BILLION RUPEES

Further company coverage: ASTR.NS

(([email protected];;))

May 21 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - RECEIVED PERMISSION FOR VOLUNTARY WITHDRAWAL OF INDICATION OF OLAPARIB (LYNPARZA)

• ASTRAZENECA PHARMA INDIA LTD - INDICATION FOR TREATMENT OF PATIENT WITH GBRCA MUTATION AND ADVANCED OVARIAN CANCER

Source text for Eikon: ID:nBSE6MWs23

Further company coverage: ASTR.NS

(([email protected];;))

March 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - RECEIVED PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION OF TRASTUZUMAB DERUXTECAN LYOPHILIZED POWDER

• ASTRAZENECA PHARMA INDIA LTD - RECEIVED PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA

Source text for Eikon: ID:nBSE1W8hCD

Further company coverage: ASTR.NS

(([email protected];;))

March 11 (Reuters) - Mankind Pharma Ltd MNKI.NS:

• ASTRAZENECA PHARMA INDIA, CO PARTNER TO ACCELERATE ACCESS TO ASTHMA MEDICINE FOR PATIENTS IN INDIA

• ENTERED AGREEMENT FOR EXCLUSIVE DISTRIBUTION OF ASTRAZENECA’S SYMBICORT BRAND IN INDIA

• ASTRAZENECA TO RETAIN INTELLECTUAL PROPERTY RIGHTS TO BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

• ASTRAZENECA TO CONTINUE TO BE MARKETING AUTHORISATION HOLDER AND IMPORT LICENSE

Further company coverage: MNKI.NS

(([email protected];))

Feb 23 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - BSE AND NSE HAVE IMPOSED A FINE OF 217,120 RUPEES EACH ON CO

Source text for Eikon: ID:nNSE36qQzl

Further company coverage: ASTR.NS

(([email protected];))